TrialBritish journal of haematology2016

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.

Dai Chihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.